Evolus (NASDAQ:EOLS) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Evolus (NASDAQ:EOLS) in a research note released on Tuesday morning, Benzinga reports. The firm currently has a $27.00 price objective on the stock.

Several other research analysts have also recently issued reports on the company. Barclays upgraded Evolus from an equal weight rating to an overweight rating and increased their price objective for the stock from $10.00 to $16.00 in a research report on Monday, January 29th. Needham & Company LLC reiterated a buy rating and issued a $22.00 price objective on shares of Evolus in a research report on Wednesday, May 8th.

Evolus Price Performance

Evolus stock opened at $12.45 on Tuesday. Evolus has a 12 month low of $7.07 and a 12 month high of $15.43. The company has a debt-to-equity ratio of 6.54, a current ratio of 3.21 and a quick ratio of 2.96. The business has a 50 day simple moving average of $12.96 and a 200-day simple moving average of $11.91. The stock has a market capitalization of $779.37 million, a PE ratio of -11.86 and a beta of 1.47.

Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Thursday, March 7th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The firm had revenue of $61.00 million during the quarter, compared to analyst estimates of $61.14 million. Equities analysts predict that Evolus will post -0.61 earnings per share for the current year.

Insider Buying and Selling at Evolus

In other Evolus news, Director David N. Gill sold 3,643 shares of the company’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $12.72, for a total value of $46,338.96. Following the sale, the director now owns 40,682 shares of the company’s stock, valued at $517,475.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Sandra Beaver sold 5,672 shares of the stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $13.92, for a total transaction of $78,954.24. Following the sale, the chief financial officer now owns 154,201 shares of the company’s stock, valued at $2,146,477.92. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director David N. Gill sold 3,643 shares of the stock in a transaction on Monday, May 13th. The shares were sold at an average price of $12.72, for a total value of $46,338.96. Following the sale, the director now directly owns 40,682 shares in the company, valued at approximately $517,475.04. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 61,628 shares of company stock valued at $830,947. Insiders own 6.10% of the company’s stock.

Institutional Trading of Evolus

Large investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. boosted its stake in shares of Evolus by 353.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,614 shares of the company’s stock valued at $70,000 after acquiring an additional 5,155 shares during the last quarter. AJOVista LLC acquired a new stake in shares of Evolus during the fourth quarter valued at $70,000. Tradition Wealth Management LLC boosted its stake in shares of Evolus by 44.8% during the fourth quarter. Tradition Wealth Management LLC now owns 8,000 shares of the company’s stock valued at $84,000 after acquiring an additional 2,475 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Evolus by 13.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 12,345 shares of the company’s stock valued at $113,000 after acquiring an additional 1,484 shares during the last quarter. Finally, Sierra Summit Advisors LLC acquired a new stake in shares of Evolus during the fourth quarter valued at $119,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.